Table II.

Summary of microRNA-based therapies tested in pre-clinical models of atherosclerosis.

microRNA-based therapies	Effect(s)	References
Anti-miR-148a	Reduction of LDL-C, and increase of LDLR, ABCA1 and HDL-C levels in transgenic mice	13
Anti-miR-122	Reduction of plasma triglycerides and cholesterol levels in mice	16
MiR-30c overexpression	Reduction of hyperlipidemia and atherosclerosis development in ApoE−/− mice	21
Anti-miR-33	Increase in HDL levels, enhancement of cholesterol efflux, and reduction of atherosclerosis in LDLR−/− and ApoE−/− mice and primates.	23, 24, 31, 33
Anti-miR-33	No alteration of atherosclerosis development in LDLR−/− mice	34
MiR-126-5p overexpression	Increase of endothelial cell proliferation and reduction of atherosclerosis in ApoE−/− mice	56
Anti-miR-92a	Reduction of endothelial inflammation and atherosclerosis development in LDLR−/− mice	59
Anti-miR-33	Increase of anti-inflammatory M2 macrophages, and reduction of atherosclerosis in LDLR−/− mice	67
Anti-miR-155	Reduction of atherosclerotic lesion formation in ApoE−/− mice	68–70
Anti-miR-155	Enhancement of atherosclerotic development in LDLR−/− mice	71